Search
Sanara Medtech Inc
SMTIAdd to Watchlist
24.840USD
+0.570+2.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
227.66MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.35%
5 Days
+4.02%
1 Month
+12.30%
6 Months
+7.53%
Year to Date
+6.38%
1 Year
-16.22%
Key Figures
24.270Open
24.860High
26.37KVolume
LossP/E TTM
33.64P/E Dynamic
--Dividend TTM
0.29%Turnover Ratio
24.270Prev. Close
24.201Low
394.01KTurnover
LossP/E Static
32.39P/B
0.00%Div Yield TTM
0.75%ROA
35.95052wk High
0.78Volume Ratio
-9.66MNet Profit
9.17MShares
-3.8918EPS TTM
1.22Beta
2.89%ROE
16.04752wk Low
2.72%Amplitude
90.97%Gross Margin
227.66MMarket Cap
2.79Reward/Risk
3.49%Risk Rate
TradingKey Stock Score of Sanara Medtech Inc
Currency: USD Updated: 2026-07-02Key Insights
Sanara Medtech Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.33.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanara Medtech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sanara Medtech Inc Highlights
StrengthsRisks
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.67% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 103.12M.
Overvalued
The company’s latest PE is -6.38, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.42M shares, decreasing 29.68% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 7.59K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
34.333
Target Price
+41.46%
Upside Space
Sanara Medtech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sanara Medtech Inc Info
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Ticker SymbolSMTI
CompanySanara Medtech Inc
CEOMuppalla (Suresh V)
Websitehttps://sanaramedtech.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Sanara Medtech Inc (SMTI)?
The current price of Sanara Medtech Inc (SMTI) is 24.84.
What is the symbol of Sanara Medtech Inc?
The ticker symbol of Sanara Medtech Inc is SMTI.
What is the 52-week high of Sanara Medtech Inc?
The 52-week high of Sanara Medtech Inc is 35.95.
What is the 52-week low of Sanara Medtech Inc?
The 52-week low of Sanara Medtech Inc is 16.05.
What is the market capitalization of Sanara Medtech Inc?
The market capitalization of Sanara Medtech Inc is 227.66M.
Is Sanara Medtech Inc (SMTI) currently rated as Buy, Hold, or Sell?
According to analysts, Sanara Medtech Inc (SMTI) has an overall rating of Buy, with a price target of 34.33.
What is the Earnings Per Share (EPS TTM) of Sanara Medtech Inc (SMTI)?
The Earnings Per Share (EPS TTM) of Sanara Medtech Inc (SMTI) is -4.36.